Diagnostic procedures and treatment of patients with Myelodysplastic Syndromes (MDS) of low and intermediate-1 risk. Results of the outpatient MDS registry

被引：0
|
作者：
Schmitz, S.
Boettger, I
Schnell, R. [1 ]
Lerchenmueller, C. [2 ]
Sauer, A. [3 ]
Severin, K.
Germing, U. [4 ]
Steinmetz, H. T.
机构：
[1] Pioh Praxis Internist Onkol & Hamatol, Frechen, Germany
[2] Gemeinschaftspraxis Hamatol & Onkol G, Munster, Germany
[3] MVZ Hamatol Onkol, Potsdam, Germany
[4] Univ Dusseldorf, D-40225 Dusseldorf, Germany
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：148 / 148
页数：1
相关论文
共 50 条
  • [31] Prospective Changes of Cardiac and Hepatic Iron and Cardiac Function in Low and Intermediate-1 Risk MDS Patients
    Pepe, Alessia
    Meloni, Antonella
    Carulli, Giancarlo
    Oliva, Esther Natalie
    Arcioni, Francesco
    Storti, Sergio
    Neri, Maria Giovanna
    Grassedonio, Emanuele
    Renne, Stefania
    Restaino, Gennaro
    Salvatori, Cristina
    Positano, Vincenzo
    Rizzo, Michele
    [J]. BLOOD, 2014, 124 (21)
  • [32] ARCADE (20090160): A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND TRIAL OF DARBEPOETIN ALFA IN THE TREATMENT OF ANEMIA IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Platzbecker, U.
    Symeonidis, A.
    Oliva, E.
    Goede, J. S.
    Delforge, M.
    Mayer, J.
    Badre, S.
    Gasal, E.
    Mehta, B.
    Franklin, J.
    [J]. HAEMATOLOGICA, 2016, 101 : 15 - 15
  • [33] Treatment of transfusional iron overload with deferasirox in patients with low and intermediate-1 risk MDS: Results from a German multi-center trial
    Nolte, F.
    Hoechsmann, B.
    Luebbert, M.
    Platzbecker, U.
    Haase, D.
    Lueck, A.
    Gattermann, N.
    Giagounidis, A.
    May, C.
    Leismann, O.
    Junkes, A.
    Schumann, C.
    Hofmann, W. -K
    Schrezenmeier, H.
    [J]. ONKOLOGIE, 2011, 34 : 290 - 290
  • [34] A Phase 3 Randomized Placebo (PBO)-Controlled Double-Blind Trial of Darbepoetin Alfa in the Treatment of Anemia in Patients with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndromes (MDS)
    Platzbecker, Uwe
    Symeonidis, Argiris
    Oliva, Esther N.
    Goede, Jeroen S.
    Delforge, Michel
    Mayer, Jiri
    Slama, Borhane
    Badre, Sejal
    Gasal, Eduard
    Mehta, Bhakti
    Franklin, Janet
    [J]. BLOOD, 2016, 128 (22)
  • [35] Cytogenetic Evolution (CE) In Patients (pts) with Low and Intermediate Risk Myelodysplastic Syndromes (MDS) Is Associated with Poor Prognosis
    Li, Liunan
    Jabbour, Elias
    Borthakur, Gautam
    Faderl, Stefan
    Kadia, Tapan
    Ravandi, Farhad
    Pierce, Sherry A.
    Wierda, William G.
    Abruzzo, Lynne V.
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    [J]. BLOOD, 2010, 116 (21) : 1212 - 1212
  • [36] Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry
    Madry, Krzysztof
    Lis, Karol
    Fenaux, Pierre
    Bowen, David
    Symeonidis, Argiris
    Mittelman, Moshe
    Stauder, Reinhard
    Cermak, Jaroslav
    Sanz, Guillermo
    Hellstrom-Lindberg, Eva
    Langemeijer, Saskia
    Malcovati, Luca
    Germing, Ulrich
    Holm, Mette Skov
    Guerci-Bresler, Agnes
    Culligan, Dominic
    Sanhes, Laurence
    Kotsianidis, Ioannis
    van Marrewijk, Corine
    Crouch, Simon
    de Witte, Theo
    Smith, Alex
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2023, 200 (04) : 451 - 461
  • [37] ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE AT DIAGNOSIS IN AN EUROPEAN REGISTRY FOR LOW RISK AND INTERMEDIATE-1 RISK MDS: REPORT ON THE FIRST 322 PATIENTS
    Stauder, R.
    Smith, A.
    de Witte, T.
    Droste, J.
    Fenaux, P.
    Symeonidis, A.
    Hellstrom-Lindberg, E.
    Sanz, G.
    Cermak, J.
    Georgescu, O.
    Germing, U.
    MacKenzie, M.
    Beyne-Rauzy, O.
    Bowen, D.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 131 - 132
  • [38] Treatment of myelodysplastic syndrome (MDS) with cytokine immunotherapy for low-risk MDS
    Kadia, Tapan M.
    Kantadian, Hagop
    Verstovsek, Srdan
    Newman, Beth
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    [J]. BLOOD, 2007, 110 (11) : 438A - 438A
  • [39] DIAGNOSIS, PROGNOSTICATION AND TREATMENT OF MYELODYSPLASTIC SYNDROMES (MDS) IN DAILY PRACTICE: RESULTS FROM THE DUTCH POPULATION-BASED PHAROS MDS REGISTRY
    Dinmohamed, A.
    Visser, O.
    Posthuma, W.
    Huijgens, P.
    Sonneveld, P.
    van de Loosdrecht, A.
    Jongen-Lavrencic, M.
    [J]. HAEMATOLOGICA, 2015, 100 : 487 - 487
  • [40] A PHASE 3 RANDOMIZED PLACEBO (PBO)-CONTROLLED DOUBLE-BLIND TRIAL OF DARBEPOETIN ALFA IN LOW OR INTERMEDIATE-1 (INT-1) RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Platzbecker, U.
    Symeonidis, A.
    Oliva, E.
    Goede, J.
    Delforge, M.
    Mayer, J.
    Slama, B.
    Badre, S.
    Gasal, E.
    Mehta, B.
    Franklin, J.
    [J]. HAEMATOLOGICA, 2017, 102 : 484 - 484
12345